Table 2.
Dose Reduction and Discontinuation for Oral Targeted Agents
| Drug | Dose (mg) | No. of Patients | Disease | % of Patients With Dose Reduction | % of Patients Who Discontinued Treatment | Reference |
|---|---|---|---|---|---|---|
| Sorafenib | 400 | 299 | NSCLC | N/R | 17.7 | Wakelee et al21 |
| Sorafenib | 400 | 355 | RCC | 52.1 | 9.3 | Rini et al22 |
| Sorafenib | 400 | 229 | HCC | 72.5 | 40.6 | Kudo et al23 |
| Sorafenib | 400 | 129 | RCC | 34.9 | 22.5 | Naito et al24 |
| Sorafenib | 400 | 62 | RCC | 30.6 | 6.5 | Procopio et al25 |
| Sorafenib | 400 | 71 | OC/PPC | N/R | 12.7 | Matei et al26 |
| Sorafenib | 400 | 82 | SCLC | N/R | 23.2 | Gitlitz et al27 |
| Sorafenib | 400 | 55 | UC | 40 | 3.6 | Nimeiri et al28 |
| Sorafenib | 400 | 64 | PC | N/R | 6.3 | Safarinejad29 |
| Sorafenib | 400 | 51 | NSCLC | 27.5 | 11.8 | Blumenschein et al30 |
| Sorafenib | 400 | 52 | RCC | 28.8 | N/R | Di Lorenzo et al31 |
| Sorafenib | 400 | 452 | RCC | 13 | 10 | Escudier et al32 |
| Sorafenib | 400 | 97 | RCC | 33 | 11.4 | Escudier et al33 |
| Sorafenib | 400 | 51 | HCC | 33.3 | N/R | Yau et al34 |
| Sorafenib | 400 | 150 | HCC | 30.7 | 14.7 | Cheng et al35 |
| Sorafenib | 400 | 56 | WDTC | 52 | 33.9 | Kloos et al36 |
| Sorafenib | 400 | 297 | HCC | 26 | 38 | Llovet et al(37 |
| Sorafenib | 400 | 55 | PC | N/R | N/R | Steinbild et al38 |
| Sorafenib | 400 | 137 | HCC | N/R | 19.7 | Abou-Alfa et al39 |
| Sorafenib | 400 | 202 | RCC | N/R | 4.4 | Ratain et al40 |
| Median, sorafenib | 33 | 12.7 | ||||
| Mean, sorafenib | 36.5 | 16.8 | ||||
| Sunitinib | 50 | 51 | Pleural mesothelioma | 41.2 | 9.8 | Nowak et al41 |
| Sunitinib | 50 | 146 | RCC | 36.3 | 15.8 | Motzer et al42 |
| Sunitinib | 37.5 | 143 | RCC | 42.7 | 17.5 | |
| Sunitinib | 37.5 | 56 | Biliary CA | 21.4 | 17.9 | Yi et al43 |
| Sunitinib | 37.5 | 119 | RCC | 32.8 | 10.1 | Barrios et al44 |
| Sunitinib | 50 | 84 | NSCLC | 17.9 | 19 | Gervais et al45 |
| Sunitinib | 37.5 | 64 | NSCLC | 26.6 | 12.5 | Novello et al46 |
| Sunitinib | 50 | 52 | Gastric CA | 9.6 | 3.8 | Moehler et al47 |
| Sunitinib | 37.5 | 83 | PNET | 31.3 | 18.1 | Raymond et al48 |
| Sunitinib | 50 | 74 | PACA | 28.4 | 9.4 | O'Reilly et al49 |
| Sunitinib | 50 | 51 | RCC | 78.4 | 25.4 | Tomita et al50 |
| Sunitinib | 50 | 78 | Gastric CA | 18 | 30.8 | Bang et al51 |
| Sunitinib | 37.5 | 238 | Breast CA | 28.2 | 15.1 | Barrios et al52 |
| Sunitinib | 37.5 | 107 | RCC | 43 | 15 | Escudier et al53 |
| Sunitinib | 50 | 375 | RCC | 50 | 19 | Motzer et al54 |
| Sunitinib | 37.5 | 60 | GIST | 23.3 | 6.7 | George et al55 |
| Sunitinib | 50 | 61 | RCC | N/R | 11.5 | Rini et al56 |
| Sunitinib | 50 | 107 | NET | 47.7 | 10.3 | Kulke et al57 |
| Sunitinib | 50 | 64 | Breast CA | 39.1 | N/R | Burstein et al58 |
| Sunitinib | 50 | 63 | NSCLC | 22.2 | 49.2 | Socinski et al59 |
| Sunitinib | 50 | 84 | CRC | 31 | 8.3 | Saltz et al60 |
| Sunitinib | 50 | 105 | RCC | N/R | 11.4 | Motzer et al61 |
| Sunitinib | 50 | 63 | RCC | 35 | 3.17 | Motzer et al62 |
| Median, sunitinib | 31.3 | 13.8 | ||||
| Mean, sunitinib | 33.5 | 15.4 | ||||
| Pazopanib | 800 | 290 | RCC | N/R | 16 | Sternberg et al63 |
| Pazopanib | 800 | 240 | STS | 38.3 | 15.4 | van der Graaf et al64 |
| Pazopanib | 800 | 74 | Cervical CA | N/R | 17.6 | Monk et al65 |
| Pazopanib | 800 | 225 | RCC | 31.1 | 15.1 | Hutson et al66 |
| Pazopanib | 800 | 142 | STS | 23.2 | 6.3 | Sleijfer et al67 |
| Vandetanib | 300 | 617 | NSCLC | N/R | 12.1 | Lee et al68 |
| Vandetanib | 300 | 72 | WDTC | 22.2 | 33.3 | Leboulleux et al69 |
| Vandetanib | 300 | 231 | MTC | 35.1 | 12.1 | Wells et al2 |
| Vandetanib | 300 | 623 | NSCLC | N/R | 14.4 | Natale et al70 |
| Vandetanib | 300 | 83 | NSCLC | N/R | 26.5 | Natale et al71 |
| Vandetanib | 300 | 73 | NSCLC | N/R | N/R | Heymach et al72 |
| Vandetanib | 300 | 52 | SCLC | N/R | N/R | Arnold et al73 |
| Axitinib | 5 | 359 | RCC | 34 | 7.5 | Motzer et al74 |
| Axitinib | 5 | 64 | RCC | 65.6 | 20.3 | Tomita et al75 |
| Axitinib | 5 | 62 | RCC | 45.2 | 35.5 | Rini et al76 |
| Axitinib | 5 | 60 | Thyroid CA | 38.3 | 13.3 | Cohen et al77 |
| Axitinib | 5 | 52 | RCC | 28.8 | 19.2 | Rixe et al78 |
| Regorafenib | 160 | 133 | GIST | N/R | 7.5 | Demetri et al79 |
| Regorafenib | 160 | 500 | CRC | 37.6 | 17 | Grothey et al80 |
| Cabozantinib | 100 | 171 | PC | 62 | 24 | Smith et al1 |
| Cabozantinib | 140 | 220 | MTC | 79 | 27 | Schoffski et al81 |
| Tivozanib | 1.5 | 260 | RCC | 9 | 8 | Nosov et al82 |
| Cediranib | 45 | 53 | RCC | N/R | 11.3 | Mulders et al83 |
| Median, all | 33.2 | 14.9 | ||||
| Mean, all | 36 | 16.4 |
NOTE. Values were obtained from publications listed, clinicaltrials.gov, information contained in package inserts, meeting abstract presentations, and US Food and Drug Administration announcements.
Abbreviations: CA, cancer; CRC, colorectal carcinoma; GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; MTC, medullary thyroid cancer; NET, neuroendocrine tumor; N/R, not reported; NSCLC, non-small cell lung cancer; OC, ovarian cancer; PACA, pancreatic adenocarcinoma; PC, prostate carcinoma; PNET, pancreatic neuroendocrine tumor; PPC, primary peritoneal cancer; RCC, renal cell carcinoma; SCLC, small cell lung cancer; STS, soft tissue sarcoma; UC, uterine carcinoma/carcinosarcoma; WDTC, well-differentiated thyroid cancer.